CNSP
CNS Pharmaceuticals Inc
$
6.479
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.6465
Open
6.6465
VWAP
6.53
Vol
4.73K
Mkt Cap
2.99M
Low
6.4502
Amount
30.89K
EV/EBITDA(TTM)
--
Total Shares
845.28K
EV
-9.85M
EV/OCF(TTM)
--
P/S(TTM)
--
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Show More
1 Analyst Rating
1196.40% Upside
Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 84.00 USD with a low forecast of 84.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
1196.40% Upside
Current: 6.479
Low
84.00
Averages
84.00
High
84.00
1196.40% Upside
Current: 6.479
Low
84.00
Averages
84.00
High
84.00
Alliance Global Partners
James Molloy
Buy
maintain
$4 -> $7
2025-05-22
Reason
Alliance Global Partners
James Molloy
Price Target
$4 -> $7
2025-05-22
maintain
Buy
Reason
Alliance Global Partners analyst James Molloy raised the firm's price target on CNS Pharmaceuticals to $7 from $4 pre-reverse-split and keeps a Buy rating on the shares after the company announced Q1 results and a quarterly update last week. The company recently pivoted to focusing on its TPI-287 candidate for Glioblastoma Multiforme after its lead candidate berubicin failed to meet the primary endpoint of a pivotal Phase 2 trial, notes the analyst, who is removing berubicin from the firm's valuation. The firm, which notes that CNS executed a 50:1 reverse split in Q1, values TPI-287 at $5.25 per share and cash and technology at $1.75 per share.
Maxim Group
Jason McCarthy
Strong Buy
to
Hold
Downgrades
n/a
2025-03-25
Reason
Maxim Group
Jason McCarthy
Price Target
n/a
2025-03-25
Downgrades
Strong Buy
to
Hold
Reason
Maxim analyst Jason McCarthy downgraded CNS Pharmaceuticals to Hold from Buy after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$0.5
2024-09-10
Reason
Maxim Group
Jason McCarthy
Price Target
$0.5
2024-09-10
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for CNS Pharmaceuticals Inc (CNSP.O) is -0.21, compared to its 5-year average forward P/E of -8.34. For a more detailed relative valuation and DCF analysis to assess CNS Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.34
Current PE
-0.21
Overvalued PE
24.56
Undervalued PE
-41.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+22.36%
-4.34M
Operating Profit
FY2025Q1
YoY :
+21.34%
-4.30M
Net Income after Tax
FY2025Q1
YoY :
-99.84%
-1.58
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CNSP News & Events
Events Timeline
2025-07-18 (ET)
2025-07-18
08:05:51
CNS Pharmaceuticals announces 1-for-12 reverse stock split
2025-06-05 (ET)
2025-06-05
08:18:01
CNS Pharmaceuticals to present on TPI 287 at Brain Tumor Biotech Summit
2025-05-16 (ET)
2025-05-16
08:16:59
CNS Pharmaceuticals sees cash runway into 2h26
Sign Up For More Events
Sign Up For More Events
News
2.0
07-20TipRanksUpcoming Stock Splits This Week (July 21 to July 25) – Stay Invested
9.0
05-13NASDAQ.COMCNS Pharmaceuticals Acquires Orphan Drug Designation For TPI 287 And Prices $5M Public Offering
8.5
04-14Business InsiderCNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants
Sign Up For More News
People Also Watch
OTRK
Ontrak Inc
0.428
USD
-2.73%
CTNT
Cheetah Net Supply Chain Service Inc
1.757
USD
0.00%
CHEK
Check Cap Ltd
0.666
USD
0.00%
IPDN
Professional Diversity Network Inc
2.240
USD
0.00%
PNBK
Patriot National Bancorp Inc
1.740
USD
+4.82%
JCSE
JE Cleantech Holdings Ltd
0.980
USD
0.00%
WAFU
Wah Fu Education Group Ltd
1.400
USD
0.00%
RDHL
Redhill Biopharma Ltd
1.330
USD
0.00%
STRR
Star Equity Holdings Inc
2.340
USD
+16.42%
PAVM
PAVmed Inc
0.456
USD
+2.94%
FAQ
What is CNS Pharmaceuticals Inc (CNSP) stock price today?
The current price of CNSP is 6.4795 USD — it has decreased -1.39 % in the last trading day.
What is CNS Pharmaceuticals Inc (CNSP)'s business?
What is the price predicton of CNSP Stock?
What is CNS Pharmaceuticals Inc (CNSP)'s revenue for the last quarter?
What is CNS Pharmaceuticals Inc (CNSP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CNS Pharmaceuticals Inc (CNSP)'s fundamentals?
How many employees does CNS Pharmaceuticals Inc (CNSP). have?